Wed, July 17, 2024

Matthew Sykes Maintained (CDNA) at Strong Buy with Increased Target to $16 on, Jul 17th, 2024

Matthew Sykes of Goldman Sachs, Maintained "CareDx, Inc" (CDNA) at Strong Buy with Increased Target from $14 to $16 on, Jul 17th, 2024.

Matthew has made no other calls on CDNA in the last 4 months.



There are 5 other peers that have a rating on CDNA. Out of the 5 peers that are also analyzing CDNA, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Yi Chen of "HC Wainwright & Co." Reiterated at Hold on, Friday, May 31st, 2024
  • Andrew Cooper of "Raymond James" Downgraded from Buy to Hold on, Monday, May 13th, 2024


These are the ratings of the 3 analyists that currently disagree with Matthew


  • Connor Chamberlain of "Craig-Hallum" Maintained at Strong Buy with Increased Target to $22 on, Friday, May 17th, 2024
  • Mason Carrico of "Stephens & Co." Maintained at Buy with Increased Target to $18 on, Monday, May 13th, 2024
  • Alexander Nowak of "Craig-Hallum" Upgraded from Hold to Strong Buy and Increased Target to $15 on, Wednesday, May 1st, 2024